// App-Quantinova.ai

OT2-1-01 : Fulvestrant alone versus fulvestrant and everolimus versus fulvestrant, everolimus and anastrozole: A Phase III randomized, placebo-controlled trial in postmenopausal patients with hormone-receptor-positive stage IV breast cancer: SWOG-Clinical Trials Initiative (CTI)* S1222

Researchers

Presenter

  • Somlo G

Principal Investigators

  • Barlow W

  • Moore HGralow JSchott A

  • Hayes D

  • Kuhn P

  • Hicks J

  • Lew D

  • Tripathy D

  • Hortobagyl G

Medical Centers

  • Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

  • University of Southern California, Los Angeles, CACleveland Clinic Foundation, Cleveland, OHUniversity of Washington, Seattle, WA

  • 1.MD Anderson Cancer Center, Houston, TX

  • SWOG Statistical Center, Seattle, WA

  • University of Michigan, Ann Arbor, MI

  • City of Hope Cancer Center, Duarte, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating tumor cells

  • Human epidermal growth factor receptor 2

  • Serine/threonine-protein kinase mTOR

  • Hormone receptor

Drug/Treatment

  • Anastrozole

  • Fulvestrant

  • Everolimus

Outcome

  • N/A

Study Design

  • randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved